SG11201502792TA - Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof - Google Patents

Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Info

Publication number
SG11201502792TA
SG11201502792TA SG11201502792TA SG11201502792TA SG11201502792TA SG 11201502792T A SG11201502792T A SG 11201502792TA SG 11201502792T A SG11201502792T A SG 11201502792TA SG 11201502792T A SG11201502792T A SG 11201502792TA SG 11201502792T A SG11201502792T A SG 11201502792TA
Authority
SG
Singapore
Prior art keywords
listerial
expression
preparation
methods
signal peptide
Prior art date
Application number
SG11201502792TA
Other languages
English (en)
Inventor
Peter M Lauer
William G Hanson
Justin Skoble
Meredith Lai Ling Leong
Marcella Fasso
Dirk Brockstedt
Thomas W Dubensky
Original Assignee
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Inc filed Critical Aduro Biotech Inc
Publication of SG11201502792TA publication Critical patent/SG11201502792TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Physics & Mathematics (AREA)
SG11201502792TA 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof SG11201502792TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261746237P 2012-12-27 2012-12-27
US201361780744P 2013-03-13 2013-03-13
PCT/US2013/078119 WO2014106123A1 (en) 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
SG11201502792TA true SG11201502792TA (en) 2015-05-28

Family

ID=51017446

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201502792TA SG11201502792TA (en) 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
SG10201700916SA SG10201700916SA (en) 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201700916SA SG10201700916SA (en) 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Country Status (13)

Country Link
US (2) US9663557B2 (zh)
EP (1) EP2938627B1 (zh)
JP (2) JP2016503655A (zh)
KR (1) KR102160322B1 (zh)
CN (1) CN104955835B (zh)
AU (2) AU2013370210B2 (zh)
BR (1) BR112015015076A2 (zh)
CA (1) CA2888727A1 (zh)
EA (1) EA201590397A8 (zh)
HK (1) HK1215260A1 (zh)
MX (1) MX2015008329A (zh)
SG (2) SG11201502792TA (zh)
WO (1) WO2014106123A1 (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
EP2288379A4 (en) 2008-05-19 2012-08-08 Advaxis DOUBLE RELEASE SYSTEM FOR HETEROLOGIST ANTIGENE
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
JP5981436B2 (ja) 2010-10-01 2016-08-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
EP3332804A1 (en) 2011-03-11 2018-06-13 Advaxis, Inc. Listeria-based adjuvants
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
WO2016011357A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
SI3253865T1 (sl) * 2015-02-06 2022-10-28 National University Of Singapore Postopki za izboljšanje učinkovitosti terapevtskih imunskih celic
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
MX2017013174A (es) * 2015-04-13 2018-04-11 Aduro Biotech Inc Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y métodos para usar los mismos.
EP3283100A2 (en) 2015-04-13 2018-02-21 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
EP3298031B1 (en) 2015-05-18 2020-10-21 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
PE20181535A1 (es) 2015-12-16 2018-09-26 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno
SG10201912074PA (en) * 2016-03-18 2020-02-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
US11440958B2 (en) 2016-11-22 2022-09-13 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
US20190038733A1 (en) 2017-08-10 2019-02-07 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
KR20200044982A (ko) 2017-09-19 2020-04-29 어드박시스, 인크. 박테리아 또는 리스테리아 균주의 동결건조를 위한 조성물 및 방법
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
AU2018373154A1 (en) 2017-11-22 2020-07-02 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
EP3536706A1 (en) 2018-03-09 2019-09-11 BiOMVis Srl Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof
AU2019231783B2 (en) 2018-03-09 2023-11-16 Advaxis, Inc. Compositions and methods for evaluating attenuation and infectivity of Listeria strains
CN110408634B (zh) * 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
WO2019210034A1 (en) 2018-04-27 2019-10-31 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
EP3725371A1 (en) 2019-04-18 2020-10-21 BiOMVis Srl Method for the production of outer membrane vesicles and immunogenic compositions thereof
CN110499324A (zh) * 2019-09-02 2019-11-26 中生康元生物科技(北京)有限公司 一种用于鉴定肿瘤新抗原的细菌表达载体及筛选鉴定肿瘤新抗原的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5552284A (en) 1991-03-29 1996-09-03 Genentech, Inc. Detection of interleukin-8 receptors by nudeic acid hybridization
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
JP2004500405A (ja) * 2000-03-29 2004-01-08 ザ　トラスティーズ　オブ　ザ　ユニバーシティー　オブ　ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
EP1320602A2 (en) 2000-09-21 2003-06-25 The Regents Of The University Of California Spas-1 cancer antigen
US7794728B2 (en) 2002-05-29 2010-09-14 The Regents Of The University Of California Attenuated Listeria spp. and methods for using the same
EP1575500A4 (en) 2002-07-12 2007-01-03 Univ Johns Hopkins MESOTHELIN VACCINE AND MODEL SYSTEMS
KR20060130038A (ko) 2003-10-15 2006-12-18 메디뮨 인코포레이티드 리스테리아에 의거한 ＥｐｈＡ２ 백신
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US7858097B2 (en) 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
SI1991263T1 (sl) * 2006-03-01 2015-03-31 Aduro Biotech Listeria spremenjena z inĹľeniringom ter postopki za njenjo uporabo
WO2008008311A1 (en) 2006-07-10 2008-01-17 The Trustees Of The University Of Pennsylvania Methods for administering tumor vaccines
JP2010534058A (ja) * 2007-04-16 2010-11-04 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性のないリステリア菌およびその構築および使用方法
CA2724649A1 (en) * 2008-05-19 2009-11-26 Anza Therapeutics, Inc. Compositions comprising prfa* mutant listeria and methods of use thereof
GB201010389D0 (en) 2010-06-21 2010-08-04 Ist Superiore Sanita Antibody derivatives
HUE039747T2 (hu) 2010-11-17 2019-02-28 Aduro Biotech Inc Eljárások és kompozíciók EGFRVIII-ra való immunválasz indukálására
EP3332804A1 (en) * 2011-03-11 2018-06-13 Advaxis, Inc. Listeria-based adjuvants
BR112014022662A2 (pt) * 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria

Also Published As

Publication number Publication date
JP6671408B2 (ja) 2020-03-25
CN104955835B (zh) 2020-04-17
CN104955835A (zh) 2015-09-30
AU2013370210A8 (en) 2016-06-23
EP2938627A4 (en) 2016-12-14
EA201590397A1 (ru) 2016-02-29
HK1215260A1 (zh) 2016-08-19
EP2938627A1 (en) 2015-11-04
CA2888727A1 (en) 2014-07-03
WO2014106123A8 (en) 2016-06-16
BR112015015076A2 (pt) 2018-10-30
KR20150099738A (ko) 2015-09-01
JP2016503655A (ja) 2016-02-08
AU2013370210A1 (en) 2015-06-18
EA201590397A8 (ru) 2016-08-31
EP2938627B1 (en) 2019-03-20
US9663557B2 (en) 2017-05-30
SG10201700916SA (en) 2017-03-30
US20170253637A1 (en) 2017-09-07
AU2018203555A1 (en) 2018-06-07
WO2014106123A1 (en) 2014-07-03
US20140186387A1 (en) 2014-07-03
JP2018135355A (ja) 2018-08-30
KR102160322B1 (ko) 2020-09-25
AU2013370210B2 (en) 2018-06-14
MX2015008329A (es) 2016-03-01

Similar Documents

Publication Publication Date Title
HK1215260A1 (zh) 促進抗原序列的李斯特菌表達的信號肽融合配偶體以及其製備和使用方法
HK1247628A1 (zh) 多特異性fab融合蛋白及其使用方法
ZA201502991B (en) Disubstituted amino acids and methods of preparation and use thereof
IL241787B (en) Human fcrn-binding modified antibodies and methods of their use
ZA201404962B (en) Modified mini-hepcidin peptides and methods of using thereof
HK1204261A1 (zh) 免疫原性 肽及其使用方法
SI2945647T1 (sl) Imunogeni peptidi WT-1 in postopki za uporabo le-teh
EP2581389A4 (en) FUSION PROTEIN FROM EXENDIN-4 AND ANALOG FROM THIS AND THE PRODUCTION PROCESS THEREFOR AND USE THEREOF
EP2874642A4 (en) Anti-inflammatory proteins and peptides, and methods for their preparation and use
EP2877854A4 (en) FUSION PROTEINS AND METHOD THEREFOR
ZA201404712B (en) Composite antigenic sequences and vaccines
IL233481A0 (en) Peptides and methods of using them
EP3029072A4 (en) Glp-1 analog fusion protein and preparation method and use thereof
IL241418A0 (en) Improved methods of use for recombinant human secretoglobins
EP2975062A4 (en) PREPARATION AND USE OF DIMERIZED FUSION PROTEIN
HUS2200014I1 (hu) Hosszan ható polipeptidek és eljárás azok elõállítására és beadására
HK1216395A1 (zh) 疫苗及使用方法
EP3078677A4 (en) Antigen chimera, antigen combination, vaccine, method of preparing same, and kit thereof
EP2968469A4 (en) PEPTIDES COMPRISING NON-ENDOGENIC AMINO ACIDS AND METHODS OF MAKING AND USING SAME
SG11201404312VA (en) Method of synthesizing peptides, proteins and bioconjugates
EP2922870A4 (en) IMMUNOMODULATORY PEPTIDES AND METHODS OF USE
IL239671A0 (en) Stable form of fusion proteins of signal transducing protein, and methods for their use and preparation
IL245273A0 (en) Long-acting polypeptides and methods for their preparation and administration